---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126493"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:53:36.763107+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Oncology appoints Peter Lebowitz as independent director; NCG, Compensation committees; option grant

## Summary
- Board size increased to nine; Lebowitz appointed as Class I director.
- Lebowitz is independent and serves on NCG and Compensation committees.
- Received one-time option for 63,350 shares at $8.72/share (closing price on 3/24/2026).
- Standard indemnification agreement executed covering expenses from board service.
- No disclosable transactions under Reg S-K Item 404(a) involving Lebowitz.

## SEC filing metadata
- accession: 0001193125-26-126493
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/0001193125-26-126493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526126493/d126641d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126493
- JSON: https://secwatch.observer/filing/0001193125-26-126493.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126493.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.